Pre-Trial Testing for Alzheimer's Drug
Contact and place of performance
Renee Kale
Not specified
RFQ due date extended to 8/20/2025 @ 10am Eastern COMBINED SYNOPSIS/SOLICITATION FOR COMMERCIAL ITEMS General Information Description This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 in conjunction with Part 13 of Federal Acquisition Regulation (FAR), as supplemented with additional information included in this notice. This announcement constitutes t...
View moreThe RPO-East Research and Development Contracting Office is seeking to obtain services for IND Testing of Alzheimer’s drug. The Statement of Work (SOW) is incorporated in Attachment 1.
Clauses and provisions as well as complete instructions for submitting a response to this solicitation and applicable provisions and clauses are found in Attachment 2. All offerors are advised to pay careful attention to the quote submission instructions as there are very specific instructions as what is required to be provided.
The period of performance (POP) is estimated to be 9/28/2025-9/27/2027.
Any award resulting from this solicitation will be issued on a Standard Form 1449. This is a combined synopsis/solicitation and therefore no 1449 was issued for the solicitation IAW FAR 12.603 (b)
NOTE: To receive an award resulting from this solicitation, offerors MUST be registered in the System for Award Management (SAM) database. Registration may be done online at: www.acquisition.gov or www.sam.gov.
Contractors are advised that any and all questions concerning this solicitation must be sent in writing via email. Questions shall be sent via email (no phone calls) to Ms. Renee Kale at [email protected]. No questions will be answered after 7 August 2025 @10am.
This is a new requirement.
Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to the Contracting Officer: Renee Kale at [email protected].
Point of Contact
Renee Kale
Contracting Officer
The Department of Veterans Affairs, RPO East Research and Development Contracting Office, is seeking laboratory services for Investigational New Drug testing of an Alzheimer’s drug under solicitation number 36C24E25Q0056. This new requirement involves drug chemistry testing and is classified under NAICS 541380 Testing Laboratories and Services and PSC Q301 Medical- Laboratory Testing. This procurement is conducted as a combined synopsis and solicitation for commercial items and is issued with a set-aside status of NONE; explanation: NONE.
The estimated period of performance for these services is September 28, 2025, through September 27, 2027. Responses to this Request for Quote must be submitted by August 20, 2025, at 10:00 AM Eastern. To receive an award, offerors must be registered in the System for Award Management database. Renee Kale is the primary point of contact for this requirement.
The solicitation documentation includes four attachments: a Statement of Work for Drug Chemistry Testing, specific instructions for quote submission, and a pricing sheet. All technical questions were required to be submitted in writing by August 7, 2025. This acquisition is being competed as unrestricted for businesses meeting the $19.0 million size standard.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.